Kaishan Tao
- Cancer Research top 2%
- MicroRNA in disease regulation 16
- Cancer-related molecular mechanisms research 10
- Hepatology top 2%
- Liver physiology and pathology 16
- Oncology top 5%
- Cancer Cells and Metastasis 9
- Molecular Biology top 5%
- Circular RNAs in diseases 9
- RNA modifications and cancer 7
- Immunology top 10%
-
- Organ Transplantation Techniques and Outcomes 16
- Xenotransplantation and immune response 8
- Cited by
- Cancer ResearchHepatologyOncology
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Kaishan Tao
102 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 127
- Cancer Research 921
- Hepatology 422
- Oncology 646
- Molecular Biology 1.5k
- Immunology 304
Countries citing papers authored by Kaishan Tao
This map shows the geographic impact of Kaishan Tao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaishan Tao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaishan Tao more than expected).
Fields of papers citing papers by Kaishan Tao
This network shows the impact of papers produced by Kaishan Tao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaishan Tao. The network helps show where Kaishan Tao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kaishan Tao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 6 | |
| 4 | Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADDbreakdown → | 2024 | 60 |
| 5 | 2024 | 2 | |
| 6 | 2022 | 19 | |
| 7 | 2022 | 4 | |
| 8 | 2021 | 60 | |
| 9 | 2020 | 8 | |
| 10 | [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells]. | 2018 | 3 |
| 11 | 2018 | 0 | |
| 12 | 2018 | 34 | |
| 13 | 2018 | 1 | |
| 14 | Pig Liver Xenotransplantation: A Review of Progress Toward the Clinic | 2016 | 5 |
| 15 | 2016 | 2 | |
| 16 | 2016 | 8 | |
| 17 | 2015 | 22 | |
| 18 | 2012 | 26 | |
| 19 | 2012 | 19 | |
| 20 | 2012 | 17 |
About Kaishan Tao
Kaishan Tao is a scholar working on Hepatology, Cancer Research and Transplantation, having authored 108 papers that have together received 2.9k indexed citations. Recurring topics across this work include Liver physiology and pathology (16 papers), MicroRNA in disease regulation (16 papers), Organ Transplantation Techniques and Outcomes (16 papers), Cancer-related molecular mechanisms research (10 papers), Cancer Cells and Metastasis (9 papers), Circular RNAs in diseases (9 papers), Xenotransplantation and immune response (8 papers) and RNA modifications and cancer (7 papers). The work is most often cited by research in Cancer Research (921 citations), Hepatology (422 citations) and Oncology (646 citations). Kaishan Tao has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Kefeng Dou, Dou Ke-feng, Nan You, Wenjie Song, Bai Ruan, Zhuochao Zhang, Xisheng Yang, Zhao-Xu Yang, Qike Huang and Weihui Liu.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.